Abstract. Gamma-emitting radiopeptides are useful for scintigraphy of tumours on the basis of receptor binding. Likewise, R-emitting radiopeptides may be used in radionuclide therapy of such tumours. As iodine-131 suggested to be suitable for this purpose, experiments were performed using three somatostatin analogues, in which the effects of coupling of a therapeutic dose of ~31I to such peptides were investigated. This study deals with the radioiodination of very small amounts of peptide on a therapeutic scale, the required purification procedures after radioiodination, and the influence of high beta fluxes from 131I on a peptide during radioiodination and purification. Based on the regularly used therapeutic doses of ~31I in cancer treatment and our previous experience with [lllIn-DTPA-D-Phel]-octreotide, it was assumed that a minimal effective therapeutic dose of 3.7 GBq 131I has to be coupled to a maximum of =100 gg peptide, representing only a slight excess of peptide over 13~I. This contrasts with non-peptide radiopharmaceuticals in which high compound to radionuclide ratios are usually used. Labelling at low peptide to radionuclide ratios (low labelling yields) results in the formation of di-iodinated compounds, whereas at high peptide to radionuclide ratios (high labelling yields) mono-iodinated products of low specific activity are formed. Thus, after radioiodination the desired mono-iodinated peptide has to be separated from unreacted iodide, and from di-iodinated and unreacted peptide, as both compounds compete for the receptors. Possible radiolysis of the peptide during labelling and separation steps were investigated by irradiating 30 gg unlabelled peptide with 370 MBq 131I in a small volume. The peptide composition of the incubation mixtures was investigated by high-performance liquid chromatography after irradiation for 30 min to 24 h. The results showed that the peptide was degraded with a half-life of less than 1 h. During the preparation of a real therapeutic dose (at much higher R-flux) the peptide will be degraded even faster during the various 
Introduction
Recently, increasing attention has been paid to scintigraphy of various processes containing receptors for peptide hormones by the application of radiolabelled analogues of these hormones. Following [123I-Tyr3]-octreotide, [111In-DTPA-D-Pheq-octreotide (known as Octreoscan 111) is nowadays extensively used for scintigraphy of somatostatin receptor-positive tumours [1] [2] [3] . Furthermore, an increasing number of publications is reporting on the use of other radioactive peptides for scintigraphic demonstration of various tumours and infectious processes [4] [5] [6] [7] [8] [9] . In the case of high tumour accumulation, such peptides may also be used for radionuclide therapy, similar to 131I-iodide in the treatment of thyroid cancer and 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma and phaeochromocytoma.
Obviously, 131I has been proposed for labelling of somatostatin analogues for radionuclide therapy of somatostatin receptor-positive tumours [10, 11] . We assume that for radionuclide therapy with 13tI-labelled peptides similar doses as are used in 131I-iodide [12] and 131I-MIBG therapy [13] will be required. Usually, only a limited amount of a bioactive peptide hormone can be administered without pharmacological side-effects, which may become a limiting factor in the coupling of a therapeutic amount of radionuclide to such a peptide. Therefore, for safety reasons it has been deemed advisable not to exceed the 100 gg dose range in i.v. administration of radiolabelled somatostatin analogues. Furthermore, with 100 gg i.v. octreotide, somatostatin receptors will become saturated. Based on our experience with [14, 15] , it was estimated that an effective therapeutic dose of =3.7 GBq (38 nmol) 131I has to be coupled to =100 gg (67 nmol) of a somatostatin analogue (M=l.5 kDa), i.e. nearly a twofold excess of peptide over radionuclide. This is in sharp contrast to the high molar compound to radionuclide ratios of most radiopharmaceuticals. Table 1 shows these ratios for some radiotherapeutic agents. However, as described previously [16] , radioiodination of [Tyr3]-octreotide using only a small excess of peptide over radionuclide results in a considerable amount of di-iodinated [Tyr3]-octreotide, which no longer binds to the somatostatin receptor [17] . Therefore, we investigated the results of radiolabelling of two somatostatin analogues, [Tyr3]-octreotide and [DTPA-D-Phel]-RC-160 ( Fig. 1) , at different molar peptide to nuclide ratios, simulating conditions during the preparation of a therapeutic dose. 125I was used as a model for ~31I because of its wellcharacterized specific radioactivity. During the necessary high-performance liquid chromatography (HPLC) and/or SEP-PAK purification steps after labelling on a therapeutic scale with 131I, high beta fluxes originate due to the concentration of the radiola- belled peptides in narrow zones of column material. Therefore, radiolytic effects under therapeutic circumstances were simulated by exposing unlabelled peptide in a small volume to a high dose of 13q-beta radiation over various time intervals. Afterwards, the radiation damage was investigated by HPLC.
Materials and methods
Peptides. Quality control of unlabelled peptides. The original peptides were analysed by reversed-phase HPLC with a Waters 600 E multisolvent delivery system connected to a g-Bondapak-Cl8 reversedphase column (300x3.9 ram, particle size 10 gin) with UV detection (254 nm). Elution was carried out at a flow rate of 1 ml/min with a linear gradient of 40%-80% (v/v) methanol in 50 mM Naacetate buffer (pH 5.5) for 20 rain and the composition was maintained for another 5 rain.
Radioiodination of peptides and quality control of radioiodinated peptides.
[Tyr3]-octreotide and [DTPA-D-Phel]-RC-160 were radioiodinated with 125I as described previously [16] .
[Tyr3]-octreotide (4.3-105 gg) was labelled with 125I (92.5-370 MBq), corresponding to molar peptide to radionuclide ratios of 1.7-43.
[DTPA-D-Phea]-RC-160 (1.3-1251.tg) was labelled with 125I (37-370 MBq), corresponding to molar peptide to radionuclide ratios of 1.7-31. After radiolabelling, the peptide components in the reaction mixture were isolated on a SEK-PAK C18 reversed-phase extraction cartridge as described previously [16] , and analysed with the HLPC system described above. Eluted radioactivity was monitored on-line using an NaI probe connected to a Canberra singlechannel analyser with a recorder. Collected fractions were measured by routine scintillation counting. Isolated peaks were concentrated and reinjected into the HPLC system in order to confirm the integrity of the radiolabelled peptide.
Investigation of radiolysis of peptides during purification steps.
The effects of high beta fluxes emanating from a therapeutic dose of 131I on microgram amounts of unlabelled peptide were investigated, simulating geometrical conditions during the mandatory purification steps. For this purpose [DTPA-D-Phel]-octreotide was used, as only of this octreotide analogue was sufficient pure compound available. In nine different irradiation experiments a well-defined amount of 131I (370 MBq in 167 ~tl 0.05 M phosphate) was incubated for 0.5-24 h at room temperature with [DTPA-DPhel]-octreotide (30 ~tg in 150 gl 0.05 M acetic acid) in a small polyethylene cup. The radiation absorbed dose in the reaction volume amounted to 130 Gy/h. Radiolysis under these circumstances was investigated by HPLC with UV detection of the unlabelled peptide and its degradation products at 254 nm. In a control experiment in the absence of 1311, the stability of the peptide was tested at room temperature without irradiation.
Results

Peptide composition before and after radioiodination
The HPLC elution pattern (monitored at 254 nm) of -octreotide yielded 96%/4%, 75%/25% and 60%/40% mono-/di-iodinated peptide, respectively. In the case of labelling of [DTPA-D-Pheq-RC-160 at molar peptide to 125I ratios of 17 and 1.7, 82% and 56% of the labelled peptides were mono-iodinated, respectively. Thus, at higher molar peptide to radionuclide ratios far more mono-iodinated than di-iodinated peptides are formed. In the case of [DTPA-D-Phe 1]-RC-160, the HPLC elution profile of the monoiodinated compound shows three peaks, like that of the original unlabelled compound. After reinjection of each of these three peaks into the HPLC the same three original peaks were again observed, indicating that this peptide exists in three interconvertable forms (data not shown). o, Original peptide; dp, degradation products inal peptide nor any degradation product was detected in the HPLC eluate (data not shown). The irradiation experiment shows that the original peptide is destroyed under these conditions with a half-life of less than 1 h (Fig.  5) . In a control experiment the peptide remained intact for 24 h at room temperature in the absence of 131I (data not shown).
Discussion
With the growing number of publications on somatostatin receptor scintigraphy, the question arises as to whether peptides also may be used in radionuclide therapy of somatostatin receptor-positive lesions. Usually, radiopharmaceuticals are prepared using a high compound to radionuclide ratio, resulting in labels with low specific activity. Because in most instances radionuclide therapy is based on mechanisms with high accumulation capacity, this is usually no drawbacks. Thus, radionuclide therapy is usually not limited by the mass of the administered radiopharmaceutical. However, in radionuclide receptor therapy a much higher specific activity is required. As in this case compounds are accumulated by specific, saturable receptor binding, efficient radionuclide receptor therapy requires an optimal mass of peptide with sufficient activity of a suitable radionuclide. Depending on the physical characteristics of the radionuclide and the metabolic properties of the radiolabelled compound, radionuclide receptor therapy requires a similar amount of radiation as is used in radioiodide therapy of thyroid cancer, i.e. equivalent to a minimal dose of 3700 MBq 131I. Such a dose has to be coupled with a small amount of peptide.
Optimal mass of peptide
In order to deliver the highest possible radiation dose to a tumour, an optimal mass of peptide labelled with high activity is required. This mass is dependent on various, often unknown, parameters, such as saturation (administered mass and endogenous peptide) and up-or downregulation of receptors at higher peptide doses. Ligandspecific accumulation of [111in_DTPA_D_Phel]_octreo_ tide in somatostatin receptor-positive tissues was initially increased by injecting more peptide [18] . Similar observations showed enhanced visualization of tumours in patients during octreotide treatment [19] [20] [21] [22] . Scintigraphy after administration of [llqn_DTPA_D_Phel]_octreo_ tide with different amounts of unlabelled [DTPA-DPhea]-octreotide suggested an optimal range of 5-120 gg (3.3-80 nmol) peptide [14] . When [llqn-DTPA-D-Phel]-octreotide was used therapeutically for the first time, it was in this same dose range [15] . However, routine octreotide treatment is performed with daily subcutaneous doses of several hundred micrograms of octreotide, probably causing upregulation of receptors [19] [20] [21] [22] ; consequently octreotide in blood will not attain the level reached after i.v. administration of 100 gg, as is used in radionuclide therapy. Intravenous administration of higher doses of (nnlabelled) peptide will therefore only saturate receptors without the desired radiotherapeutic effect. Furthermore, not only receptor occupation but also unwanted pharmacological side-effects may limit the administration of bioactive peptides. Therefore, the highest radionuclide tumour uptake (% dose) is assumed to be achieved with 100 gg (67 nmol) of 1.5-kDa somatostatin analogue. Independent of the used radionuclide, an equivalent mass of radiolabelled somatostatin analogue will thus be required for radionuclide therapy, assuming that its metabolic properties are comparable to those of [111in_DTPA_D_Phel]_octreotide.
Choise of a suitable radionuclide
Recently, in addition to radionuclides emitting mediumand high-energy beta particles, attention has been paid to radionuclides that are commonly used for gamma camera scintigraphy. It is suggested that these radionuclides may also find therapeutic use on the basis of their low energetic conversion and Auger electrons. The radiation energy of these electrons is deposited within the direct vicinity of the disintegrating radionuclide. This category includes gallium-67 and indium-111 [23] [24] [25] [26] . The question arises as to whether such a radionuclide, coupled to a peptide, is sufficiently internalized by the cell that the emitted low-energy particles will reach the nucleus. That this may be the case was suggested by the successful treatment of a glucagonoma patient with [111In-DTPA-DPhel]-octreotide [15] . In this study we paid attention to the possibility of preparing and purifying radioiodinated peptides for peptide receptor therapy because 131I-iodide is most frequently used in therapeutic nuclear medicine (for the treatment of hyperthyroidism, goitre and thyroid cancer). In the form of 131I-MIBG, 131I is successfully used in treatment of neuroblastoma and phaeochromocytoma.
Labelling of peptides with 1MI
The proposed 3.7 GBq 131I (38 nmol, see Table 2 ) iodide must be bound to the presumed optimal mass (100 gg=67 nmol peptide). Incorporation of more than one iodine atom into the tyrosine of [Tyr3[-octreotide results in the loss of receptor binding [17] . Although the use of 131I is more appropriate to test the different labelling conditions, this radionuclide is not available in the welldefined specific activity required for the molar-ratio experiments. Therefore, 125I was used as a model because of its known specific activity (8xl 0 x6 Bq/mol).
Our peptide experiments with 125I demonstrate that low excesses of peptide over radionuclide result in relatively large fractions of di-iodinated compounds, while a (Figs.  2, 3) , with, of course, much peptide remaining unlabelled. Preparative HPLC separations will therefore be required to separate the wanted radiopeptide from unlabelled peptide, di-iodinated peptide and unreacted radioiodide. The radiopeptide is concentrated in very small volumes during necessary purification on HPLC and/or SEP-PAK columns and, hence, is subject to radiolytic damage (Fig. 5) . Radiolytic damage can be prevented using a suitable radiation quencher such as gentisic acid [27] , but its radiation quenching effect cannot be guaranteed during the SEP-PAK and HPLC purification steps. Therefore, 131I seems unsuitable for radionuclide somatostatin receptor therapy. An additional drawback of the use of radioiodine for peptide receptor therapy is that 13JI will be released from tumours in the same way as such release occurs after the administration of antibody fragment-bound radioiodine [28] . Conversely, radiometals that are chelated to antibody fragments tend to be retained by tumours [28] . Therefore, in the following, a one-step alternative approach will be discussed in which, instead of 131I, residualising radiometals, such as yttrium, are used in the presence of a radiation quencher.
Direct radiolabelling of chelator-coniugated peptides with radiometals
A well-known method in the daily practice of nuclear medicine is the simple one-step preparation of radiopharmaceuticals that does not require additional purification steps. Such direct radiolabelling can be performed in the presence of a suitable radiation quencher and will therefore be preferred for preparing radiopeptides for therapy. Peptides and proteins conjugated with polyaminopolycarboxylic acids such as EDTA, DTPA and DOTA are suitable for such a one-step labelling procedure with radiometals. 11 Tin and 90y are frequently used to label proteins conjugated with DTPA groups for diagnostic and therapeutic purpose respectively. Although the binding between 90y and DTPA appeared to be stable in vitro, this radionuclide is released from the DTPA group in vivo, resulting in unfavourable bone accumulation [29] . This is especially the case when one acetic acid group of DTPA is linked to the protein and, hence, is not available for 90y complexation [29] . In carbon backbone-linked DTPA groups, such as SCN-Bz-DTPA, 90y is far more tightly bound under physiological conditions, probably because all five carboxyl groups participate in 90y complexation. In addition, peptides may also be derivatized with polyazamacrocycles, such as the DOTA group, that bind 90y with very high affinity [30] . Recently, preliminary animal experiments with an octadentate octreotide derivative labelled with 90y showed promising results with respect to in vivo stability as well as inhibition of tum0ur growth [31 ] . Furthermore, somatostatin analogues have been coupled successfully with rhenium-188 using a 188W/188Re generator and routine kit coupling, although metabolic properties (hepatobiliary clearance and low tumour to normal tissue ratios) will limit their use in humans [32, 33] . Other therapeutic radiometals suitable for one-step radionuclide coupling, such as terbium-161 (included in the DTPA group), are not yet generally available.
In the absence of a convenient and suitable method for obtaining 131I-labelled peptides, the one-step labelling procedure using chelator-conjugated peptides to bind beta-decaying radiometals, such as 90y, l l4mIn (decaying to the ~-emitting 114In) and 161Tb, will be the current method of choise, although the availability of ultrapure radionuclides is still limited. Such radiolabelling will have to meet the same specific activity requirements as are described above (i.e. the highest possible activity of a radionuclide coupled to the optimal mass of peptide), which seems possible for many short-lived radionuclides in the absence of their isotopes and other metallic contaminants. In Table 2 the theoretical numbers of mols corresponding to 3.7 GBq of some radionuclides are compared with the attainable values in practice. This illustrates that certainly not all short-lived radionuclides will reach the high therapeutic specific activity required for coupling a high therapeutic radionuclide dose to a relatively small amount of peptide. 90y is a good candidate in this respect, but few if any peptides are available conjugated with a suitable chelator such as the DOTA group. Our preliminary experience shows that ~61Tb binds well to [DTPA-D-Phel]-octreotide [34] and may be suitable for radionuclide receptor therapy. Finally, the problem of high physiological accumulation of chelatorconjugated radiopharmaceuticals in vital organs, such as the kidneys, deserves further investigation.
Conclusion
Intact mono-iodinated 13~I-labelled somatostatin analogues are hard to obtain in radiotherapeutic amounts, since further separations are necessary during which radiation damage to the peptide will occur due to enrichment of the radionuclide in small volumes. For peptide receptor radionuclide therapy direct labelling of a radio-metal such as 90y or a61Tb to a chelator-conjugated peptide in the presence of a suitable radiation quencher appears far more easily attainable. A second advantage may be that radiometals will probably be better retained in tumours than radioiodine. However, many problems regarding radionuclide purity and synthesis of suitable chelator-conjugated peptides remain to be solved.
